Lamictal Buyers Urge 3rd Circ. To Revive Pay-For-Delay Case
By Melissa Lipman ( June 16, 2014, 7:58 PM EDT) -- Drug purchasers challenging a no-authorized-generic settlement between GlaxoSmithKline PLC and Teva Pharmaceutical Industries ltd. told the Third Circuit on Friday that the U.S. Supreme Court's recent pay-for-delay ruling didn't create a new safe haven for some kinds of pharmaceutical patent settlements....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.